Fig 2: SARS-CoV-2-specific T cells from patients with MS on anti-CD20 treatment are functional(A–C) Correlation of ?IFN-? SFUs measured by FluoroSpot with percentages of LFA-1+ IFN-?+ T cells stimulated with anti-CD3 (n = 34) or four SARS-CoV-2 peptides (N, S, S1, and M, n = 34) or only N and S1 SARS-CoV-2 peptides in pwMS and HC (n = 30).(D) Representative dotplots of LFA-1 and IFN-? expression of total CD3+ T cells with corresponding IFN-? FluoroSpot image of one HC and one pwMS under anti-CD20 treatment.(E) Repartition of LFA-1+ IFN-?+ specific T cells between CD4 and CD8 among pwMS with anti-CD20 treatment following stimulation as in (A–C) (n = 14 or 15) and with EBV peptides (n = 4).(F) Representative dotplots of CD4+ T cell expression of LFA-1 with CD40L, IFN-?, TNF, and GM-CSF from one HC and one pwMS with anti-CD20 treatment following a culture with medium or in the presence of SARS-CoV-2 peptides N and S1.(G–J) Percentages of LFA-1+CD40L+, LFA-1+IFN-?+, LFA-1+TNF+, and LFA-1+GM-CSF+ among CD4+ T cells in HC (n = 8) and pwMS with anti-CD20 treatment (n = 18) or with other therapies (n = 7). Spearman r and p values are shown. Dots represent individual data points. Box plots represent median and 95% CI. See also Figure S2. CLD = cladribine; DMF = dimethyl fumarate; DN = double-negative; DP = double-positive; EBV = Epstein-Barr virus; HC = healthy controls; MFI = median fluorescent intensity; NTZ = natalizumab; pwMS = persons with multiple sclerosis; RTX = rituximab; SFU = spot forming unit.